Literature DB >> 3447907

Implications of pharmacokinetic modeling in risk assessment analysis.

R J Lutz1, R L Dedrick.   

Abstract

Physiologic pharmacokinetic models are a useful interface between exposure models and risk assessment models by providing a means to estimate tissue concentrations of reactive chemical species at the site of action. The models utilize numerous parameters that can be characterized as anatomical, such as body size or tissue volume; physiological, such as tissue blood perfusion rates, clearances, and metabolism; thermodynamic, such as partition coefficients; and transport, such as membrane permeabilities. The models provide a format to investigate how these parameters can influence the disposition of chemicals throughout the body, which is an important consideration in interpreting toxicity studies. Physiologic models can take into account nonlinear effects related to clearance, metabolism, or transport. They allow for extrapolation of tissue concentration from high dose to low dose experiments and from species to species and can account for temporal variations in dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3447907      PMCID: PMC1474455          DOI: 10.1289/ehp.877697

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  20 in total

1.  Pharmacokinetic considerations on resistance to anticancer drugs.

Authors:  R L Dedrick; D S Zaharko; R A Bender; W A Bleyer; R J Lutz
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant.

Authors:  T Terasaki; T Iga; Y Sugiyama; M Hanano
Journal:  J Pharm Pharmacol       Date:  1982-09       Impact factor: 3.765

3.  Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example--vinyl chloride.

Authors:  P J Gehring; P G Watanabe; C N Park
Journal:  Toxicol Appl Pharmacol       Date:  1978-06       Impact factor: 4.219

4.  Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat.

Authors:  Y Igari; Y Sugiyama; S Awazu; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

5.  A general scheme for the incorporation of pharmacokinetics in low-dose risk estimation for chemical carcinogenesis: example--vinyl chloride.

Authors:  M W Anderson; D G Hoel; N L Kaplan
Journal:  Toxicol Appl Pharmacol       Date:  1980-08       Impact factor: 4.219

6.  A preliminary pharmacokinetic model for several chlorinated biphenyls in the rat.

Authors:  R J Lutz; R L Dedrick; H B Matthews; T E Eling; M W Anderson
Journal:  Drug Metab Dispos       Date:  1977 Jul-Aug       Impact factor: 3.922

7.  Pharmacokinetic model for 2-amino-1,3,4-thiadiazole in mouse, dog, and monkey.

Authors:  F G King; R L Dedrick
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

8.  Mechanisms of carcinogenesis: dose response.

Authors:  P J Gehring; G E Blau
Journal:  J Environ Pathol Toxicol       Date:  1978 Sep-Oct

9.  Species similarities in pharmacokinetics.

Authors:  R L Dedrick; K B Bischoff
Journal:  Fed Proc       Date:  1980-01

10.  Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver.

Authors:  M E McManus; A Monks; J M Collins; R White; J M Strong
Journal:  J Pharmacol Exp Ther       Date:  1981-12       Impact factor: 4.030

View more
  2 in total

Review 1.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

2.  Assessment of human exposure to chemicals from Superfund sites.

Authors:  M A Kamrin; L J Fischer; W A Suk; J R Fouts; E Pellizzari; K Thornton
Journal:  Environ Health Perspect       Date:  1994-01       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.